Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
Enveda raised $311M, doubling its valuation to $2B, to push more AI‑driven natural‑product drugs into clinical trials.
Why Now
The funding round, led by Catalio Capital Management with Iconiq and others, followed a $155M Series D that valued the company at $1B a year earlier.
What Happened
Enveda, founded in 2019 by Viswa Colluru, uses AI to discover drugs from plants and microbes. The Series E brings the total valuation to $2 billion and the company is testing drugs for severe skin conditions and post‑GLP‑1 weight‑loss maintenance.
Why It Matters
The capital enables Enveda to accelerate clinical testing of nature‑derived candidates, potentially expanding the pipeline of non‑synthetic therapeutics and challenging traditional drug discovery models. It signals investor confidence in AI‑augmented biopharma.
The Limitation
The article does not detail the clinical trial outcomes or regulatory milestones, so the success of these drugs remains uncertain.
What You Can Do
Explore Enveda’s clinical trial pipeline or consider partnering with them for natural‑product drug discovery.
Source
Read original sourceWhy we picked this
Enveda’s funding and AI-driven drug discovery directly impact AI research and biotech applications.